A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study
A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study
Anna‐Maria Hoffmann‐Vold, Susanna Proudman, Jeska de Vries‐Bouwstra, Andrea Hsiu Ling Low et al.
Citations
5 citations
Journal
Journal of Scleroderma and Related Disorders
Topics
Systemic Sclerosis and Related Diseases
Field-Weighted Citation Impact (FWCI)
2.12
article
A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study
Anna‐Maria Hoffmann‐Vold, Susanna Proudman, Jeska de Vries‐Bouwstra, Andrea Hsiu Ling Low, Oliver Distler, Dinesh Khanna, Nora Fagan, Masataka Kuwana, Mary Flack, Anjli Kukreja
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Scleroderma and Related DisordersVol. 10(1)
Institutions
Oslo University Hospital (NO), Royal Adelaide Hospital (AU), National University of Singapore (SG), University of Zurich (CH), Singapore General Hospital (SG), University of Michigan (US), Leiden University Medical Center (NL), University Hospital of Zurich (CH), Scleroderma Foundation (US), Boehringer Ingelheim (United States) (US), The University of Adelaide (AU), Nippon Medical School (JP)